Last reviewed · How we verify
Bone Metastases of Solid Tumors
Approved treatments
- Zometa · Novartis
Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity. - Zometa · University of Arkansas
- Zoledronate · Children's Hospital Medical Center, Cincinnati
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Bone Metastases of Solid Tumors patent landscape — cliff calendar, originator estates, attackable patents
- Bone Metastases of Solid Tumors treatment landscape brief
- Bone Metastases of Solid Tumors treatment updates RSS
Frequently asked questions about Bone Metastases of Solid Tumors
What drugs treat Bone Metastases of Solid Tumors?
Tracked treatments include Zometa, Zoledronate.
What is the treatment for Bone Metastases of Solid Tumors?
Standard treatment for Bone Metastases of Solid Tumors includes Zometa, Zoledronate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Bone Metastases of Solid Tumors patent cliff · Bone Metastases of Solid Tumors CI report
- Treatment: Zometa · Novartis
- Treatment: Zometa · University of Arkansas
- Treatment: Zoledronate · Children's Hospital Medical Center, Cincinnati
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing